Sanjoy Dutta, PhD, Jay Skyler, MD, and other panelists will share insights on advances in the use of manufactured islets and what it might take to achieve widespread clinical use.
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.